2. Disease Areas
  3. Cancer Blood or Cardiovascular Disease
  4. Leukemia/Lymphoma/Myeloma Blood Disease
  5. Leukemia/Lymphoma/Myeloma
  6. Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Chronic myelogenous leukemia, BCR-ABL1 positive, is a chronic myeloproliferative neoplasm characterized by the presence of the BCR-ABL1 fusion gene, leading to uncontrolled proliferation of myeloid cells. It commonly affects middle-aged and older adults, presenting with symptoms such as fatigue, weight loss, anemia, night sweats, and splenomegaly, along with neutrophilic leukocytosis. The disease typically begins in a chronic phase, which may progress to an accelerated phase or blast crisis without treatment. Management involves tyrosine kinase inhibitors to target the BCR-ABL1 protein, significantly improving survival, alongside allogeneic stem cell transplantation in select cases.

Chronic Myelogenous Leukemia (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179247
    BCR-ABL1-IN-2
    BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research.
    BCR-ABL1-IN-2
  • HY-N0117AR
    (Z)-Indirubin (Standard) 906748-38-7
    (Z)-Indirubin (Standard) is the analytical standard of (Z)-Indirubin (HY-N0117A). (Z)-Indirubin is an isomer of Indirubin (HY-N0117). Indirubin is a bisindole alkaloid with significant anticancer activity against chronic myeloid leukemia.
    (Z)-Indirubin (Standard)